Novotech Publishes Duchenne Muscular Dystrophy Landscape Report to Support Biotech Research Planning
BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novotech , the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released today an industry-leading report on Duchenne Muscular Dystrophy (DMD) Clinical Trial Landscape .
- BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novotech , the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released today an industry-leading report on Duchenne Muscular Dystrophy (DMD) Clinical Trial Landscape .
- The Novotech research analyst team provides these expert reports monthly, completely free of charge.
- They tackle the hurdles faced by biotech firms in specific therapeutic areas and discuss future paths in therapy and investment trends.
- This comprehensive resource guides healthcare professionals, researchers, and organizations in navigating the complex clinical trial DMD landscape.